Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEN-SHE: Single-dose HPV vaccine efficacy in Kenya
NCT03675256Phase 4Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2018
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of human papillomavirus type 16 L1 capsid protein antigen, recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), sponsored by Massachusetts General Hospital. Started Dec 2018; status: active, not recruiting.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenrecombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT03675256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675256.